| Symbol | OCSAW |
|---|---|
| Name | OCULIS HOLDING AG |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | Switzerland |
| Telephone | 617-937-2423 |
| Fax | — |
| — | |
| Website | https://www.oculis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001953530 |
| Description | Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide. Additional info from NASDAQ: |
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Read moreOculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Read moreOculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
Read moreOculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Read moreOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
Read moreOculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
Read moreOculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
Read more